Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies

Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies

Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis characterized by extravascular granulomas and eosinophilia in both blood and tissues. Eosinophils, which play a critical role in the pathophysiology of EGPA, require interleukin (IL)-5 for maturation in the bone marrow...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mayu Shiomi, Ryu Watanabe, Ryuhei Ishihara, Sayaka Tanaka, Takashi Nakazawa, Motomu Hashimoto
Format:	Article
Language:	English
Published:	MDPI AG 2025-04-01
Series:	Biomolecules
Subjects:	benralizumab eosinophil eosinophilic granulomatosis with polyangiitis interleukin-5 mepolizumab
Online Access:	https://www.mdpi.com/2218-273X/15/4/544
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Two unique cases of eosinophilic granulomatosis with polyangiitis in childhood treated with anti-interleukin-5 therapy: infantile-onset and submandibular salivary gland involvement
by: Evangelia Constantine, et al.
Published: (2025-06-01)

INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
by: T. V. Beketova, et al.
Published: (2020-06-01)

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
by: T. V. Beketova, et al.
Published: (2021-03-01)

Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review
by: Matteo Lazzeroni, et al.
Published: (2025-07-01)

Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA
by: Mili Shum, et al.
Published: (2025-06-01)

A case of hereditary alpha tryptasemia and presumptive eosinophilic granulomatosis with polyangiitis
by: Sonia Iqbal, DO, et al.
Published: (2025-08-01)

Pituitary dysfunction with eosinophilic granulomatosis with polyangiitis presenting with diabetes insipidus: a case report and review of the literature
by: Aifei Zhang, et al.
Published: (2025-06-01)

Benralizumab treatment and 3-dimensional bronchial tree changes in chronic eosinophilic pneumonia
by: Yoshiro Kai, MD, PhD, et al.
Published: (2025-08-01)

Switching from multiple-inhaler triple therapy to single, extra fine-inhaler triple therapy in severe refractory asthma with EGPA: beyond control. Case report and review of the literature
by: Francesco Menzella, et al.
Published: (2025-04-01)

Wells’ syndrome associated with eosinophilic granulomatosis with polyangiitis − A case report
by: Radević Tatjana, et al.
Published: (2021-01-01)

A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review
by: Agata Sebastian, et al.
Published: (2024-12-01)

Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases
by: Dipti Gothi, et al.
Published: (2025-05-01)

Case Report: Coadministration of TNF-α blockade as an effective adjunctive strategy in the treatment of ANCA-negative EGPA with refractory peripheral neuropathy
by: Dabin Tang, et al.
Published: (2025-07-01)

A Rare Case of Autoimmune Pulmonary Alveolar Proteinosis Developing During the Course of Eosinophilic Granulomatosis With Polyangiitis
by: Yoichi Dotake, et al.
Published: (2025-05-01)

International guidelines for the management ofANCA-associated systemic vasculitides
by: T. V. Beketova
Published: (2019-03-01)

Peripheral neuropathy as initial manifestation of Churg-Strauss Syndrome
by: Antonio Villa, et al.
Published: (2020-03-01)

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study
by: Luisa Brussino, et al.
Published: (2025-03-01)

Eosinophilic Granulomatosis With Polyangiitis Presenting With Visual Problems and Subendocardial Fibrosis, A Case Report
by: Mahshid Talebi‐Taher, et al.
Published: (2025-04-01)

Pediatric eosinophilic granulomatosis with polyangiitis presenting as a mediastinal mass in a 6-year-old boy
by: Sagar Bishowkarma, et al.
Published: (2025-05-01)

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction
by: González-Tuyub YH, et al.
Published: (2024-11-01)

Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis
by: Durga Prasanna Misra, et al.
Published: (2019-01-01)

Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
by: T. V. Beketova, et al.
Published: (2021-12-01)

THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS
by: T. V. Beketova
Published: (2017-03-01)

New ACR/EULAR 2022 classification criteria for ANCA-associated vasculitis
by: T. V. Beketova
Published: (2023-10-01)

Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report
by: Kaburaki S, et al.
Published: (2025-04-01)

Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis
by: Christiane E. Whetstone, et al.
Published: (2025-08-01)

THE 2015 INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
by: T. V. Beketova, et al.
Published: (2016-07-01)

Unraveling cerebrovascular involvement in EGPA through digital subtraction angiography: case presentation and systematic literature review
by: Viren Vasandani, et al.
Published: (2025-07-01)

Arthritis as a clinical manifestation of antineutrophil cytoplasmic antibody-associated systemic vasculitis: diagnostic difficulties
by: T. V. Beketova, et al.
Published: (2018-06-01)

Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP
by: Garcia-Rivero JL, et al.
Published: (2025-05-01)

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings
by: M. V. Zhuravleva, et al.
Published: (2022-07-01)

Upper respiratory tract manifestations in patients with ANCA-associated vasculitides and their association with the presence and type of ANCA
by: I. G. Smirnova, et al.
Published: (2021-10-01)

Intracerebral Hemorrhage with Churg Strauss-Syndrome: Multidisciplinary Collaboration and Literature Review
by: Bai P, et al.
Published: (2024-12-01)

Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic
by: Li Lin, et al.
Published: (2025-03-01)

Damage to the organ of hearing and upper respiratory tract in vasculitis associated with antineutrophil cytoplasmic antibodies
by: A. A. Klimenko, et al.
Published: (2024-08-01)

Massive pulmonary thromboembolism in a pediatric patient with eosinophilic granulomatosis with polyangiitis: a case-based review emphasizing management
by: Batuhan Küçükali, et al.
Published: (2025-01-01)

A Classical Manifestation of Eosinophilic Granulomatosis with Polyangiitis with an Unusual Catastrophic Outcome
by: Balachandra S Bhat, et al.
Published: (2024-10-01)

Kimura disease and eosinophilic granulomatosis with polyangiitis: Clinical and imaging overlap of 2 immune-mediated conditions
by: Won Young Yoon, MBChB, BSc, et al.
Published: (2025-07-01)

Literature review and case study of recurrent EPGA with elevated IgG4 and positive HBsAg successfully treated with rituximab
by: Junru Wang, et al.
Published: (2024-12-01)

RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
by: T. V. Beketova, et al.
Published: (2014-06-01)